PLANTATION, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced the agenda for its upcoming Annual Meeting of
Stockholders to be held on Thursday, February 17, 2005 at 3:00 p.m. at the
Sheraton Suites hotel in Plantation, Florida.
Formal Voting
Stockholders of record as of December 31, 2004 are entitled to vote in the
election of three Class A directors (Charles A. Rice, Robert C. Salisbury and
Charles J. Simons) and to ratify the appointment of Ernst & Young LLP as the
Company's independent registered public accounting firm.
Special Presentations
In addition to a business update from President & CEO, Charles A. Rice,
the following speakers are scheduled to present:
* Dr. Helen Sang, Roslin Institute, Project Leader, Avian Transgenics
"Advances in Avian Transgenic Technology - A Research Update"
* Dr. William H. Stimson, Viragen's Director of Research Emeritus
"Multiferon(R) in the Adjuvant Treatment of Malignant Melanoma:
A New Approach to Prolong Survival"
* Dr. Karen Jervis, Viragen's Director of Product Development
"Envisioning Cancer Therapy with IEP 11 Peptide Technology"
A copy of the Proxy Statement, directions to the meeting and additional
information is available at: http://www.Viragen.com
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority-owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
Email: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made. Guests scheduled to present at this event are potentially
subject to be replaced or canceled due to unforeseen conflicts.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax +1-954-233-1414, or
dcalder@viragen.com
|
